NT Mobile Menu

Search form


Controversy Continues Regarding PPI Use and Dementia

Controversy Continues Regarding PPI Use and Dementia

Felicia C. Goldstein, PhD


Dr Goldstein is Professor in the department of neurology at Emory University School of Medicine.

Following last year’s study in JAMA Neurology, which linked proton pump inhibitors (PPIs) with cognitive decline and dementia, patients and clinicians grew concerned about the popular medications that treat heartburn, gastroesophageal reflux disease, and peptic ulcers—to no surprise. It is estimated that globally about 35 million people have dementia, and this number is expected to more than double in the next 20 years. This staggering number of affected people will have a huge impact on both a societal and personal level. The only alternative seems to be prevention.

PPIs are very effective in treating gastric-acid related disorders, so many question whether stopping use of PPIs is this the best course of action. Critics argue that the study was flawed, because it did not adjust for enough confounders. Others agree that more research is needed before making grand changes in patient care. Meanwhile, new research contradicts previous results. So how should clinicians counsel their patients?

Neurology Times invited esteemed neuropsychiatrist and dementia expert Felicia C Goldstein, PhD, to share an update on PPIs and dementia. Her latest research may have clinicians further questioning this link and resulting clinical implications.

Neurology Times (NT): What does current research show about the association between PPI use and dementia?

Dr. Goldstein: There is controversy concerning whether PPI use is associated with an increased risk of dementia. Two studies conducted in Germany in persons 75 years and older found that PPI use increased the risk of dementia and Alzheimer disease (AD).

In a multicenter German Study of Aging, Cognition, and Dementia in Primary Care Patients Haenisch and colleagues1 enrolled 3076 persons who underwent a brief cognitive screening battery and were judged to be dementia free at baseline. Compared with non-PPI users, the researchers found an increased risk of both dementia and specifically Alzheimer disease over a follow-up period of 6 years.

Another investigation by the same group2 examined the claims data diagnoses of 73,679 persons aged 75 years and older. The risk of incident dementia was greater in persons taking PPI medications.

More recently, however, conflicting findings were reported by Booker and colleagues3 who reviewed medical record information from a database in Germany of patients aged 70 to 90 years with or without a diagnosis of dementia. PPI use was associated with a decreased risk of incident dementia.

Against this background of conflicting findings concerning whether PPI use is a risk factor for dementia, my colleagues and I addressed this question in persons enrolled in the National Alzheimer Coordinating Center database consisting of 33 nationwide NIH-NIA supported Alzheimer Disease Centers.4 We evaluated the association between PPI use and the annual conversion (follow-up of 2 to 6 years) of persons with normal cognition at baseline into mild cognitive impairment (MCI) or dementia, or the annual conversion of persons with MCI at baseline into dementia. All analyses controlled for demographics (age, race, gender, education), vascular comorbidities (self-reported hypertension, diabetes, heart disease, transient ischemic attack/stroke), mood (depression), and anticholinergic and histamine-2 receptor antagonist use.

Of 10,486 eligible participants, 884 (8.4%) reported always using PPIs, 1925 (18.4%) reported intermittent use, and 7677 (73.2%) reported never using PPIs at any annual follow-up. Continuous (always vs never) PPI use was associated with a decreased risk of decline in cognitive function (HR 0.78, 95% CI 0.66-0.93, P = .005) and a decreased risk of conversion to MCI or dementia due to AD (HR 0.82, 95% CI 0.69-0.98, P = .026). Intermittent use was also associated with decreased risk of decline in cognitive function (HR 0.84, 95% CI 0.76-0.93, P = .001), and risk of conversion to MCI or dementia due to AD (HR 0.82, 95% CI 0.74-0.91, P = .001). This reduced risk was found for persons with either normal cognition or MCI.


Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.